

## County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 1<sup>st</sup> November 2018** 

## **Classification of products:**

- **G Green drug** Can be initiated and prescribed in all care settings O- Second line / alternative green drug
- G+ Green+ drug Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined these will be defined in each case.
- Amber drug These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- Red drug Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- Not Approved Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- Not Reviewed Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- Unclassed Drug Drugs that do not fall into one of the above categories

Dreadurat		Commonto/notoo						
Product	Decision			Comments/notes				
	Approved	Refused	Deferred					
1) Requests deferred from previous meetings								
None								
2) New Requests								
PLENVU® Macrogol 3350,sodium ascorbate,ascorbic acid, sodium sulphate anhydrous, electrolytes	R			For bowel cleansing in adults (>18years of age) prior to any procedure requiring a clean bowel Bowel clesansing prior to Colonoscopy and also for CT Virtual Colonoscopy in those patients who cannot tolerate Moviprep. <b>Decision:</b> Plenvu approvded as an alternative to Moviprep in patients who cannot have Picolax. The intention is not to have this as an option in the current bowel preparations protocol nor is the intention to add this product to the current PGD for bowel preparatios. Plenvu will be reserved for prescribing by a consultant.				
3) New formulations & extensions to use								
None								



County Durham and Darlington Area Prescribing Committee

and sorafenib for treating differentiated thyroid cancer after radioactive iodine is the responsible commissioner.   TA536: Alectinib for untreated ALKpositive advanced non-small-cell lung cancer is The formulary will reflect the TAG – NHS England in the responsible commissioner.   TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDS is The formulary will reflect the TAG – CCG is the responsible commissioner.   TA538: Diutuximab beta for treating neuroblastoma is it The formulary will reflect the TAG – NHS England in the responsible commissioner.   TA538: Diutuximab beta for treating neuroblastoma is it The formulary will reflect the TAG – NHS England in the responsible commissioner.   TA539: Lutetium (177Lu) oxodotrectide for treating unresectable or metastatic neuroendocrine tumours it The formulary will reflect the TAG – NHS England in the responsible commissioner.   TA540: Pembrolizumab for treating relapsed or refractory classical model in the responsible commissioner. it it eresponsible commissioner.   TA541: Inotuzumab ozogamicin for treating relapsed or refractory classical europhysical europhys	DECISION SUMMARY Area Prescribing Count						
TAS34: Dupilumab for treating moderate to severe atopic dermatitis Image: Comparison of the temperature is approximate temperatetemperature is approximate temperature is approximate temperature	Product				Comments/notes		
for treating moderate dermatitis Image: Severe acopic dermatitis Image: Severe acopic dermatitis   TA535: Lenvatinib and sorafenib for irreating differentiated thyroid cancer after adioactive iodine Image: Severe acopic dermatitis Image: Severe acopic dermatitis   TA536: Alectinib for intreated data thyroid cancer after adioactive iodine Image: Severe acopic dermatitis Image: Severe acopic dermatitis Image: Severe acopic dermatitis   TA536: Alectinib for intreated data (Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics)   TA537: Ixekizumab for treating active psoriatic arthritis after inadequate responsible commissioner. Image: Severe acopic dermatics) Image: Severe acopic dermatics)   TA538: Dinutuximab beat for treating neuroblastoma Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics)   TA539: Lutetium (177Lu) image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics)   TA540: Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics)   TA541: Inotuzumab for interating relapsed or refractory classical hodgkin lymphoma Image: Severe acopic dermatics) Image: Severe acopic dermatics) Image: Severe acopic dermatics)<	5) Products considered by NICE						
and soratenib for treating differentiated thyroid cancer after radioactive iodine the responsible commissioner.   TA536: Alectinib for untreated ALKpositive advanced non-small-cell lung cancer The formulary will reflect the TAG – NHS England i the responsible commissioner.   TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDS The formulary will reflect the TAG – CCG is the responsible commissioner.   TA538: Diutuximab beta for treating neuroblastoma Image: state inadequate responsible commissioner.   TA538: Lutetium (177Lu) oxodotreotide for treating neuroblastoma Image: state inadequate responsible commissioner.   TA540: Peembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Image: state inadequate responsible commissioner.   TA540: Prembrolizumab for treating relapsed or refractory classical exclusions to measure in the responsible commissioner. The formulary will reflect the TAG – NHS England i the responsible commissioner.   TA540: Prembrolizumab for treating relapsed or refractory classical exclusions by the APC Image: state in the responsible commissioner.   TA541: Inotuzumab acue lymphoblastic leukaemia Image: state in the responsible commissioner.   TA541: Inotuzumab Image: state in the responsible commissioner.   TA541: Inotuzumab Image: state in the responsible commissioner.   TA541: Inotuzumab Image: state in the responsible commissioner.   TA541: Inotu	for treating moderate to severe atopic	R					
untreated Is the responsible commissioner.   ALKpositive advanced non-small- cell lung cancer the responsible commissioner.   TA537: Ixekizumab for treating active psoriatic arthritis Image: Commission of the test of	and sorafenib for treating differentiated thyroid cancer after	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
Toporiatic arthritis Image: Comparison of the second s	untreated ALKpositive advanced non-small-	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
beta for treating neuroblastoma Image: Comparison of the set of	for treating active psoriatic arthritis after inadequate response to	R					
(177Lu) Image: Construct of the second s	beta for treating	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
The responsible commissioner.   treating relapsed or refractory classical Hodgkin lymphoma   TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.   The formulary will reflect the TAG – NHS England in the responsible commissioner.	(177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia Image: the responsible commissioner.   7) Appeals against earlier decisions by the APC	Pembrolizumab for treating relapsed or refractory classical	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
	ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.		
	7) Appeals against earlier decisions by the APC						
NONE	None						



County Durham and Darlington

DECISION SUMMARY				County Durnam and Darlington Area Prescribing Committee				
Product		Decision		Comments/notes				
	Approved	Refused	Deferred					
8) Products considerd by NTAG								
Ferric Maltol for the treatment of	✓ G+			The formulary will reflect the NTAG position.				
irondeficiency				Recommended as an option prior to IV				
anaemia in Inflammatory Bowel				iron and after trial of at least two oral ferrous salts.				
Disease only								
(updated)				Approved change from RED to Green+ status.				
Ferric Maltol for the treatment of	$\checkmark$			The formulary will reflect the NTAG position.				
irondeficiency	G+			Recommended as an option prior to IV				
anaemia in patients				iron and after trial of at least two oral				
without Inflammatory Bowel				ferrous salts.				
Disease								
8) Miscellaneous d	8) Miscellaneous decisions by the APC							
Opicapone 50mg	$\checkmark$			For the treatment of Parkinson's disease - second				
capsules	G+			or third line - used in patients who have tried and failed on entacapone.				
				Decision: Approved. First supply must be				
				from specialist. Is on formulary in Tees and this				
				is causing some cross boundary issues. (Also on NoT formulary)				
Enoxaparin BECAT				Decision: Approve name change on				
name change to AROVI				formulary.				
Adrenaline	$\checkmark$			Decision: Agreed to add to formulary due to current				
autoinjectors – add Emerade®	Ğ			supply issues with Epipen and Jext.				
				Also agreed to add 500microgram strength as				
				per NoT formulary for use in the emergency				
				treatment of anaphylaxis for patients with a BMI of >40 or who have required				
				more than one auto-injector previously to control				
				symptoms. Specialist immunologist initiation only.				

The following guidelines were presented to and approved at the November 2018 meeting of the APC:

- County Durham & Darlington Osteoporosis Guideline
- County Durham Homely Remedies Policy for Nursing Homes
- RMOC Free of Charge Medicines Scheme Policy

The following Green+ drug information leaflets were presented to and approved at the November 2018 meeting of the APC:

• Nil

The following shared care guidelines were presented to and approved at the November 2018 meeting of the APC:

• Nil